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TECHNICAL REPORT
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Abstract
Tumor involvement at the resection margin remains the most important predictor for local recurrence in patients with rectal
cancer. A careful description of tumor localization is therefore essential. Currently, endoscopic tattooing with ink is customary,
but visibility during laparoscopic resections is limited. Near-infrared (NIR) fluorescence imaging using indocyanine green
(ICG) could be an improvement. In addition to localize tumors, ICG can also be used to identify sentinel lymph nodes (SLNs).
The feasibility of this new technique was explored in five patients undergoing laparoscopic low anterior resection for rectal
cancer. Intraoperative tumor visualization was possible in four out of five patients. Fluorescence signal could be detected 32
±18 minutes after incision, while ink could be detected 42 ± 21 minutes after incision (p = 0.53). No recurrence was diagnosed
within three months after surgery. Ex vivo imaging identified a mean of 4.2 ± 2.7 fluorescent lymph nodes, which were
appointed SLNs. One out of a total of 83 resected lymph nodes contained a micrometastasis. This node was not fluorescent.
This technical note describes the feasibility of endoscopic tattooing of rectal cancer using ICG:nanocolloid and NIR
fluorescence imaging during laparoscopic resection. Simultaneous SLN mapping was also feasible, but may be less reliable
due to neoadjuvant therapy.
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Introduction
The introduction of total mesorectal excision (TME)
combined with preoperative radiotherapy in patients
with resectable rectal cancer has shown to reduce local
recurrence rates from 11% to 5% compared to sur-
gery alone (1). Tumor involvement at the resection
margin remains the most important predictor for local
recurrence (2). A careful description of the localiza-
tion of the rectal tumor is therefore essential. In the
era of laparoscopic surgery, this is even more chal-
lenging, especially when the tumor is small or located
at the mesenteric intestinal border. Colonoscopy is
the gold standard for detection of colorectal cancer.
However, its ability to localize cancer has been called
into question (3). Tumor localization can be wrongly
assessed when the colonoscope is not completely
straight. Endoscopic tattooing using ink to direct
the surgeon has been performed since the 1960s
(4). It results in reliable intraoperative localization,
but not all tattoos are visible, especially when the
tumor can be found below the peritoneal reflection
or adjacent to the mesorectal envelope (5).
Recently, near-infrared (NIR) fluorescence imag-
ing has been introduced for real-time intraoperative
visualization of tumors, sentinel lymph nodes (SLNs)
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and vital structures such as ureters (6). Advantages of
NIR light (wavelength 700-900 nm) include high
tissue penetration (several millimeters) and low tissue
autofluorescence, providing high signal-to-back-
ground ratios. Indocyanine green (ICG) is currently
the only clinically available 800 nm fluorophore and
has been used with success in several clinical studies
(7,8). ICG could be a more suitable dye for tattooing,
because of few side effects, relatively long absorption
time and potentially increased detection using NIR
fluorescence imaging compared to macroscopic color
perception (9).
Besides endoscopic tattooing, injecting ICG may
also assist in intraoperative detection of SLNs.
Although surgery is often considered curative in
node-negative rectal cancer, approximately 25% of
these patients will develop disease recurrence (10).
This is most likely caused by understaging of the
resected lymph nodes (LNs). Micrometastases are
easily missed by conventional histopathological
examination, but examination of all LNs to detect
micrometastases is time-consuming and expensive.
Multilevel fine pathological examination of SLNs in
colorectal cancer has been shown to improve tumor
staging (11). Several studies report high detection and
sensitivity rates by using ICG for the SLN procedure
in different types of cancer, including gastrointestinal
cancer (12–18). ICG is non-covalently absorbed
by nanocolloid. The hydrodynamic diameter is
thereby increased from 1 nm to approximately
50 nm (19,20). This improves accuracy, since mole-
cules <approximately 10 nm quickly flow through the
SLN to second tier LNs, whereas larger molecules
require multiple hours to days to reach beyond the
SLN. Using ICG-nanocolloid whether or not
combined with Technetium-99m to identify SLNs
has already successfully been described in patients
(21–23). The aim of the present study was to assess
the feasibility to localize tumors and SLNs using NIR
fluorescence imaging after endoscopic tattooing with
ICG:nanocolloid.
Material and methods
The study was approved by the Medical Ethics Com-
mittee of the Leiden University Medical Center and
performed in accordance with the ethical standards of
the Helsinki Declaration of 1975.
Laparoscopic fluorescence imaging system
Intraoperative NIR fluorescence imaging was
performed using a laparoscopic high definition fluo-
rescence imaging system (KARL STORZ GmbH &
Co. KG, Tuttlingen, Germany). The system included
a plasma light guide and a 30, 10 mm laparoscope,
applicable for white light (WL) and ICG imaging.
Switching between WL and ICG mode was done by
using a foot pedal.
Preparation and injection of the probe
ICG (25 mg vials, Pulsion Medical Systems, Munich,
Germany) was dissolved in 5ml sterile water. Subse-
quently, 1 ml of 5 mg/ml ICG was diluted in 100 ml
sterile water (50 mg/ml final concentration). Nanocol-
loid (0.5 mg vials, GE Healthcare, Eindhoven, the
Netherlands) was dissolved in 3 ml saline. 1.5 ml
50 mg/ml ICG was then mixed with 0.9 ml of
0.167 mg/ml nanocolloid. After general anesthesia,
prior to incision, 1.6 ml ICG:nanocolloid containing
100 mg nanocolloid and 50 mg ICG was injected
endoscopically at four peritumoral submucosal spots
(0.4 ml per spot) by the gastroenterologist. A rectal
tube was used to deflate the rectum after endoscopy.
Surgical technique
Included patients (Table I) underwent standard-of-
care laparoscopic low anterior resection performed by
experienced surgeons. Peritumoral tattooing with
India ink was performed by the gastroenterologist






















1 M 71 cT2N0M0 15 Radiotherapy + 5 12 +
2 M 61 cT3N2M0 7 Chemoradiotherapy + 2 15 +
3 F 65 cT3N1M0 18 Radiotherapy + 3 12 +
4 F 70 cT3N2M0 7 Chemoradiotherapy - 5 18 +
5 F 76 cT2N0M0 9 None + 4 26 +
69 ± 5.6 11.2 ± 5.0 80% 3.8 ± 1.3 16.6 ± 5.8 100%






































several weeks prior to surgery. In addition to the
standard-of-care, NIR fluorescence imaging was per-
formed at several time points during laparoscopic
surgery to localize the tumor and SLNs.
Ex vivo imaging
After slicing of the specimen at least one day after
surgery, fluorescence imaging was performed again at
the Pathology Department with the previously
described FLARE imaging system (24). Fluores-
cent LNs were appointed as SLNs and processed
separately from non-fluorescent LNs. Standard path-
ologic assessment was performed by cytokeratin
immunohistochemistry.
Results
The tumor could clearly be localized in four out of five
patients (Figure 1A). One patient (patient no. 4) was
injected with ICG:nanocolloid, but no intraoperative
images were obtained due to an operator mistake that
disabled the correct imaging settings. In all other
patients the fluorescence signal was visible earlier
than ink (Figure 1B). Fluorescence signals could be
detected 32 ± 18 minutes after incision, while ink
could be detected 42 ± 21 minutes after incision
(p = 0.53). All resections were radical. No recurrence
was diagnosed within three months after completion
of the study. One patient (no. 2) developed anasto-
motic leakage, which was closed surgically. No other
complications regarding the use of ICG:nanocolloid
or fluorescence imaging occurred.
The mean time between injection and end of the
procedure, i.e. the time for ICG:nanocolloid to
migrate to the SLN, was 189 ± 48 minutes. During
the procedure, a mean of 2.0 ± 0.82 fluorescent LNs
could be visualized (Figure 2). Ex vivo imaging was
performed in all five patients. Using the FLARE
imaging system, a mean of 4.2 ± 2.7 fluorescent LNs
per patient could be identified, which were appointed
SLNs. The pathologist found 12.4 ± 8.0 additional
LNs per patient by conventional method, which were
appointed non-SLNs. One out of a total of 83 iden-
tified LNs contained a micrometastasis. However,
this node (in patient no. 2) was not fluorescent.
Discussion
Advances in the treatment of rectal cancer have not
only led to improved patient outcome, but also to
challenges. Laparoscopic surgery results in signifi-
cantly lower mortality and morbidity compared to
open surgery (25), but it also deprives surgeons of
tactile and visual feedback. Neoadjuvant radioche-
motherapy decreases recurrence rates, but pathologic
response makes identification of the primary tumor
more difficult (5). Both laparoscopy and neoadjuvant
therapy complicate the intraoperative localization of
the tumor. These advances are especially an issue
since incomplete resections are the single most
A
B
Figure 1. (A) Intraoperative laparoscopic NIR fluorescence imag-
ing of the endoscopically injected probe ICG:nanocolloid in a
patient with rectal cancer. India ink is not yet visible. (B) Intrao-
perative macroscopic visualization of India ink in the rectum. NIR
fluorescence signal is also visible.
Figure 2. Ex vivo NIR fluorescence imaging of a resected and sliced rectum specimen using the FLARE camera system. Two fluorescent
spots are visible (white arrows), which were appointed as SLNs.






































important factor for rectal cancer recurrence (2).
Endoscopic tattooing using ink results in reliable
intraoperative localization of colorectal cancer (26).
However, not all tattoos are visible, because ink can be
easily masked by overlying tissue.
The present study shows that endoscopic tattooing
with ICG:nanocolloid is technically feasible. The NIR
fluorescence signal was visible in all patients in whom
imagingcouldbeperformed. Inaddition, the signalwas
not only seen earlier than ink, butwas also better visible
throughout the entire procedure. This is the result of a
higher penetration depth of NIR light (several milli-
meters) compared to ink.Watanabe et al. (9) also used
ICG for colonic tattooing. In all ten patients, the tumor
border could be identified using NIR fluorescence
imaging. The signal remained visible for at least 72-
120 hours after pre-operative endoscopic injection.
However, we chose to perform endoscopic tattooing
after general anesthesia to save our patients from the
discomfortof yetanothercolonoscopyandanothervisit
to the hospital. Although the tumor could be localized
tenminutes earlier, the endoscopy during surgery neu-
tralized this advantage. To be cost-effective, it should
therefore be studied whether the ICG injection can be
combinedwiththestandard-of-careendoscopic tattoo-
ingwith inkorcanevenreplace it.This is,however,only
possible if the retention time of ICG is sufficient.
In colorectal cancer patients, both blue dyes and
radiotracers have been used as SLN tracers in in vivo
and ex vivo settings, but both tracers have disadvan-
tages (27). The use of gamma ray-emitting radio-
tracers requires involvement of a nuclear physician
and localization requires a handheld gamma probe,
which does not permit real-time visualization. Blue
dyes cannot be seen through overlying tissue and can
diffuse through the true SLN to 2nd- and 3rd-tier
nodes due to their small size. The use of ICG:nano-
colloid may overcome these disadvantages and iden-
tify LNs which are candidates for multilevel fine
pathological examination (11). Other studies describ-
ing the use of ICG and NIR fluorescence imaging in
SLN identification in different types of cancer report
detection rates of 90% to 100% and sensitivity rates of
82% to 100% (12–18). The detection rate is similar
(100%), but the only micrometastasis containing
lymph node in the present study was not fluorescent
(sensitivity: 0%). Although the included number of
patients is not enough to draw extensive conclusions,
the difference may be explainable by the long course
of neoadjuvant chemoradiotherapy this patient
(patient no. 2) received, which has been shown to
result in unreliable SLN procedures in rectal cancer
(28). SLN mapping in rectal cancer using ICG:nano-
colloid and NIR fluorescence imaging appears to
perform just like other SLN mapping methods in
rectal cancer, i.e. unreliably. However, it can still
assist in identifying the necessary number of LNs
required for pathologic TNM staging (29). In addi-
tion, in case no neoadjuvant therapy is given, e.g. in
selected patients with stage cT1-cT2N0, this tech-
nique may have higher sensitivity. Arezzo et al. (25)
showed the feasibility of SLNmapping using ICG and
NIR fluorescence imaging during transanal endo-
scopic microsurgery (TEM) in three patients with
T0/T1 rectal cancer.
The currently used laparoscope was only capable of
showing one light modus at a time. However, there
are already camera systems available that can depict
white light and NIR channels at the same time, and
even produce white light-NIR overlay video for better
anatomical orientation.
ICG is not a tumor-targeted probe. Hence, no
tumor-specific signal can be expected. The accuracy
of the fluorescence signal thus depends mainly on the
accuracy of the gastroenterologist’s injection. In the
near future, tumor-specific probes, such as cRGD-
ZW800-1 which targets integrins associated with
neoangiogenesis, may be expected (30). Such probes
have the potential to accurately localize tumor and its
border in real-time during surgery. Furthermore, it
makes endoscopic tattooing redundant, because these
probes are injected intravenously prior to surgery.
Conclusion
This technical note describes the technical feasibility
of endoscopic tattooing of rectal cancer using ICG:
nanocolloid and NIR fluorescence imaging during
laparoscopic resection. Simultaneous SLN mapping
was also feasible, but may be less reliable.
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